ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,749.49
0.20%
Dow Jones
44,546.08
-0.37%
Gold vs US Dollar
2,901.99
0.67%
Brent Oil
74.875
0.86%
Bitcoin
96,284.02
0.16%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Grifols SA (GRFS)

  7. Grifols SA (GRFS) News

Grifols (GRFS)

Grifols SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GRFS
DateTimeSourceHeadlineSymbolCompany
14/01/202511:00GlobeNewswire Inc.Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s DiseaseNASDAQ:GRFSGrifols SA
11/12/202419:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
09/12/202422:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
27/11/202421:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
19/11/202420:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
19/11/202413:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
19/11/202413:00GlobeNewswire Inc.GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B VirusNASDAQ:GRFSGrifols SA
29/10/202412:00GlobeNewswire Inc.Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant SolutionNASDAQ:GRFSGrifols SA
22/10/202412:00GlobeNewswire Inc.Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye InjuryNASDAQ:GRFSGrifols SA
03/10/202412:00GlobeNewswire Inc.GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional BiothreatNASDAQ:GRFSGrifols SA
25/09/202421:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
23/09/202421:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
23/09/202410:32IH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNASDAQ:GRFSGrifols SA
22/08/202409:37IH Market NewsSchwab and Snowflake Retreat in Premarket, WeRide Postpones IPO, Halliburton Cyberattack, McDonald’s Instagram HackNASDAQ:GRFSGrifols SA
31/07/202412:00GlobeNewswire Inc.GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339NASDAQ:GRFSGrifols SA
30/07/202418:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
30/07/202415:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
29/07/202412:00GlobeNewswire Inc.Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patientsNASDAQ:GRFSGrifols SA
03/07/202410:59IH Market NewsApple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More NewsNASDAQ:GRFSGrifols SA
01/07/202410:00GlobeNewswire Inc.Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven yearsNASDAQ:GRFSGrifols SA
18/06/202411:30GlobeNewswire Inc.Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier GroupNASDAQ:GRFSGrifols SA
17/06/202408:20GlobeNewswire Inc.Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficienciesNASDAQ:GRFSGrifols SA
14/06/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
04/06/202414:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
31/05/202420:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
19/04/202420:42PR Newswire (US)Grifols 2023 Annual Report on Form 20-F filed with the SECNASDAQ:GRFSGrifols SA
18/04/202413:30GlobeNewswire Inc.Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.NASDAQ:GRFSGrifols SA
15/04/202411:06IH Market NewsSamsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More NewsNASDAQ:GRFSGrifols SA
04/04/202408:00GlobeNewswire Inc.Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus ScreeningNASDAQ:GRFSGrifols SA
22/03/202413:07IH Market NewsFedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest NewsNASDAQ:GRFSGrifols SA
 Showing the most relevant articles for your search:NASDAQ:GRFS

Your Recent History

LSE
WG.
Wood Group (john)
LSE
SYME
Supply@me Capital
LSE
PANR
Pantheon Resources
LSE
TERN
Tern
LSE
AGR
Assura
LSE
POS
Plexus
LSE
OXB
Oxford Biomedica
LSE
AAZ
Anglo Asian Mining
LSE
GWMO
Great Western Mining
LSE
GKP
Gulf Keystone Petroleum
LSE
GEX
Georgina Energy
LSE
CPX
Cap-xx
LSE
BIRD
Blackbird
LSE
EEE
Empire Metals
LSE
VAST
Vast Resources
LSE
IPO
Ip
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads